ESK-001-003
39 evidence topics · 4 sources
Objective
Pharmacokinetic and pharmacodynamic assessment for dose selection
Location and study date
Study period and single site in Glendale, United States, in the published report
“This was a phase I, single‐center, randomized, double‐blinded (with Sponsor unblinded), placebo‐controlled, parallel‐group, MD study of oral ESK‐001 immediate release tablet administration in healthy participants (NCT05431634), conducted from April 15, 2022 to September 20, 2022 at a facility in Glendale (US).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2022-05-12” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2022-12-01” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2022-12-31” (opens the source at this quote in a new tab)
“First Submitted 2022-06-09” (opens the source at this quote in a new tab)
“First Posted 2022-06-24” (opens the source at this quote in a new tab)
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2023-05-09” |
Study design
Official title and design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-003” |
| Conditions | “Safety and Tolerability” |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “Double (ParticipantInvestigator)” |
Blinding, confinement, and 14-day dosing schedule
“The Principal Investigator, clinical study personnel, and study participants were blinded to treatment with the Sponsor unblinded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following the screening period from Day −29 to −2, participants were admitted to the facility from Day −1 to 16 for a 14‐day course of the study drug with first dose administration on Day 1, and returned 5–7 days after the last dose for final safety assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization utilized a randomization code and restricted access area maintenance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory framework of the United States study
“The study adhered to the 21 Code of Federal Regulation guideline, the principles of the Declaration of Helsinki, the ICH E6 (R2) Good Clinical Practice – Scientific Guideline, the requirements of national drug and data protection laws, in particular, the Health Insurance Portability and Accountability Act of 1996.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Inclusion: age | “Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit” |
| Inclusion: health status | “Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters” |
| Inclusion: other | “Other inclusions as specified in the protocol” |
| Exclusion: prior exposure | “Participant has a prior exposure to ESK-001” |
| Exclusion: hypersensitivity | “Participant has a history of hypersensitivity to any of the ingredients of ESK-001” |
| Exclusion: other | “Other exclusions as specified in the protocol” |
| Ages eligible for study | “18 Years to 60 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Tablet strengths and matching placebo
“The study products included ESK‐001 30 mg tablet (Batch number: 25089), ESK‐001 10 mg tablet (Batch number: 25087), and matching placebos (30 mg tablet [Batch number: 25206], 10 mg tablet [Batch number: 25204]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Six dose regimens and the basis for dose and fasting conditions
“Doses were 20 mg once daily (q.d.) fasted, 20 mg once every 12 h (Q12) fasted, 40 mg Q12 fasted, 10 mg q.d. fasted, 30 mg Q12 nonfasted, and 60 mg q.d. nonfasted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dose levels were determined based on the SAD/MAD study results and relative bioavailability study data of the tablet vs. liquid formulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The fasting requirement was adjusted for the last two cohorts, based on data from the FE cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Pharmacodynamic assessments: pSTAT1 flow cytometry and whole-blood RNA sequencing
“The effect of ESK‐001 on exploratory PD and biomarker parameters was evaluated in the whole blood of healthy participants from the MD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Flow cytometry analysis of pSTAT1 (phosphorylated signal transducer and activator of transcription 1) expression in T cells in IFNα‐stimulated whole blood and RNA sequencing of unstimulated whole blood was performed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definitions of percentage pSTAT1 inhibition and the type I interferon and SIGLEC1 signatures
“The percentage inhibition of pSTAT1 was calculated for each participant for each timepoint as the percentage change from baseline (Day 1 predose).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RNA sequencing was performed to analyze type I IFN gene and SIGLEC1 signature, which were defined as the median transcript expression of the Dx Terity panel genes HERC5, RSAD2, IFI27, and IFIT1, and SIGLEC1, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Urine collection and pharmacokinetic-pharmacodynamic sampling in the multiple-dose study
“Urine was collected from all MD cohorts but only cohorts 20 mg q.d., 60 mg q.d., and 40 mg Q12 were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Parallel collection of PK samples alongside PD sampling enabled the determination of the ESK‐001 PK/PD relationship.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned cohort size and participants enrolled per cohort
“Participants were randomized to six cohorts (planned cohort size: 8 participants) to receive ESK‐001 or placebo (3:1), with 49 participants (36 for ESK‐001 and 13 for placebo) enrolled per Sponsor's decision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, June 2022, superseded in May 2023
Description of analysis sets
Steady-state assessment and software for pharmacokinetic and statistical analyses
“Plasma ESK‐001 steady state was assessed by calculating the 90% confidence interval (CI) of the slope of the linear regression of loge (concentration at the end of a dose interval [C trough]) vs. time in the MD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PK analyses were conducted using Phoenix WinNonlin Version 8.3 or higher, and all statistical analyses were performed using SAS Version 9.4 (SAS Institute, Cary, North Carolina, USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Data included in the pharmacokinetic-pharmacodynamic analysis
“All available individual PD TYK2 inhibition data points (across all valid cohorts, doses, and timepoints) with matching PK measurements were included in the assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individual PD results were plotted against their respective exposure (in μM) on a semi‐log scale graph and best‐fit curve (log inhibitor vs. response, four parameters) was generated in GraphPad Prism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Per protocol, PD samples were to be collected on Day 14, but for some participants, the PD samples were collected on Day 13.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“N = 6 participants, except for Cohort 30 mg Q12 Day 14 (N = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion of placebo participants with unexpected plasma concentrations
Results
Participant disposition
Randomization and discontinuations in the multiple-dose study
“In the MD study, 49 participants were randomized to study treatment (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five participants discontinued the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants discontinued the study drug and study due to TEAEs (see Safety and Tolerability results).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant receiving ESK‐001 (Cohort 20 mg q.d. fasted) discontinued the study drug and study after the sixth dose due to psychotic behavior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, two participants receiving placebo discontinued the study drug and study due to withdrawal by participant (both for personal reasons, non‐safety‐related); one (Cohort 40 mg Q12 fasted) after the second dose on Day 10, and another (Cohort 30 mg Q12 nonfasted) after the first dose on Day 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Race, ethnicity, sex, and body mass index in the multiple-dose study
“Most participants were white and not Hispanic or Latin (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, sex was balanced between cohorts receiving ESK‐001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean BMI ranged from 24.0 to 26.8 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Absorption, half-life, dose proportionality, steady state, and accumulation with the tablet
“ESK‐001 was rapidly absorbed into the systemic circulation with a median T max of 1.5–3.1 h on Day 1 following a single dose, and 1.1–2.2 h on Day 14 following multiple q.d. or Q12 doses (Figure 3b, Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean t½ after the last dose on Day 14 ranged from 7.6 to 12.4 h across all q.d. or Q12 doses and no trend with dose or dose regimen was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, no trend with dose was observed for geometric mean apparent steady‐state volume of distribution (Vss/F) and mean apparent total plasma clearance (CL/F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After multiple q.d. doses and after the first dose administration of Q12 doses, AUC from time zero to time tau (AUC0–tau) appeared to increase in a dose‐proportional manner (slope estimates [95% CI] were 0.934 [0.62;1.25] and 0.992 [0.49, 1.49], respectively), although 95% CIs were wide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No definitive conclusion could be derived on dose proportionality for q.d. doses on Day 1 and for Q12 doses on Day 14.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Steady state was achieved by Day 3 following q.d. and Q12 multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following multiple q.d. doses, accumulation ratios (R ac) based on C max and AUC0–tau showed no to minimal accumulation of ESK‐001 (mean R ac C max ranged from 0.71 to 1.41 and mean R ac AUC from 0.80 to 1.39).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following multiple Q12 doses, there was an ~ 2‐fold accumulation of ESK‐001 (mean R ac C max ranged from 1.74 to 2.17 and mean R ac AUC from 1.74 to 2.42).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The C trough levels at the highest ESK‐001 dose of 40 mg Q12 were maintained above the in vitro human whole blood (HWB) 90% pSTAT inhibitory concentration (IC90) threshold (Figure 3c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma pharmacokinetic parameters by multiple-dose cohort on days 1 and 14
“Summary of plasma PK parameters of ESK‐001 following administration of single and multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Urinary excretion of unchanged drug in the multiple-dose study
“Only a small amount of unchanged ESK‐001 was eliminated in urine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean %Fe (CV%) and CLr (CV%) were comparable for Cohort 60 mg q.d. (nonfasted) (0.43% [94.7%] and 63.8 mL/h [66.8%], respectively) and Cohort 40 mg Q12 (fasted) (0.37% [55.8%] and 46 mL/h [115.2%], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to one outlier participant with very high %Fe (45.4%) and CLr (24.3 L/h) compared with the other participants in the same treatment group, the mean %Fe and CLr for the Cohort 20 mg q.d. (fasted) were higher (1.12% [935.9%] and 203.7 mL/h [4430.3%], respectively) than for the Cohorts 60 mg q.d. (nonfasted) and 40 mg Q12 (fasted).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elimination route in the congress poster's summary of the multiple-dose study
Inhibition of IFNα-induced pSTAT1 in T cells by dose
“In the MD study, IFNα‐induced pSTAT1 expression was analyzed in T cells from whole blood as a measure of TYK2 inhibition and confirmed robust pharmacologic activity of ESK‐001 with a clear dose‐dependent effect (Figure 4a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maximal TYK2 pathway inhibition was achieved within 2–4 h for all doses >10 mg q.d., with dose‐dependent differences observable at later timepoints following the last dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the highest daily dose of 80 mg (administered as 40 mg Q12), maximal levels of TYK2 inhibition were achieved within 2–4 h and maintained throughout the Q12 dose interval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the lowest total daily dose of 10 mg q.d., a partial TYK2 inhibition profile was achieved, with TYK2 inhibition peaking at <50% inhibition within 2–4 h and quickly returning to baseline TYK2 activity with minimal inhibition measured at 12 and 24 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All dose levels returned toward normal TYK2 activity 24–48 h after the last dose on Day 14.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type I interferon gene signature and SIGLEC1 expression
“The mRNA transcriptomics analysis showed clear dose‐dependent inhibition of type I IFN gene signature on Day 14 with full inhibition at higher doses, which was concordant with pSTAT1 functional assay results (4b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, clear dose‐dependent inhibition of expression of SIGLEC1 (sialic acid binding Ig like lectin 1), a novel TYK2‐responsive biomarker, was observed (Figure 4c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Downstream cytokine inhibition in the congress poster
Pharmacokinetic-pharmacodynamic relationship at the highest and lowest doses
“At the highest dose of 40 mg Q12, peak (2–4 h after the last dose) and trough (12 h after the last dose) samples showed maximal TYK2 inhibition, which aligned with PK exposures at or above the in vitro HWB pSTAT IC90 threshold and was maintained throughout the treatment period (Figure 5c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As expected at the lowest dose (10 mg q.d.), ESK‐001 demonstrated only a partial profile of TYK2 inhibition with limited TYK2 inhibition achieved at peak timepoints (2–4 h after the last dose), which was not maintained at trough timepoints (24 h after the last dose) (Figure 5b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESK‐001 demonstrated a strong PK/PD relationship, with high predictability, low variability, and a clear sigmoidal exposure–response relationship with TYK2 inhibition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher levels of drug exposure above the IC90 guide point did not result in additional pharmacological effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose range selected for the STRIDE phase 2 study
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events by multiple-dose cohort
Incidence, severity, relatedness, discontinuations, and laboratory findings in the multiple-dose study
“Thirty‐eight (77.6%) participants experienced 91 TEAEs; 27 (75.0%) participants receiving ESK‐001 experienced 72 TEAEs and 11 (84.6%) participants receiving placebo experienced 19 TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most TEAEs (90.1%) were mild in severity; all other TEAEs were moderate in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no dose‐dependent increase in the number of TEAEs or meaningful change in the severity levels observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The frequency of headaches appeared to increase with increasing dose of ESK‐001; however, most headaches (80.8%) were observed to be mild in severity across all dose levels and resolved without sequalae.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants discontinued the study drug and study due to TEAEs; one participant receiving ESK‐001 (Cohort 30 mg Q12 nonfasted) due to rash morbilliform (considered study drug‐related), and one receiving placebo (Cohort 60 mg q.d. nonfasted) due to COVID‐19 (considered not study drug‐related); both TEAEs were mild in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs (reported in ≥30% of the participants in any group) by preferred term were erythema and headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Events of erythema were secondary to skin taping for a sample collection procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen (41.7%) participants receiving ESK‐001 experienced 29 TEAEs considered related to the study drug and 1 (7.7%) participant receiving a placebo experienced a TEAE considered related to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Minor fluctuations occurred in coagulation, clinical chemistry, and urinalysis parameters, but without treatment‐related trends.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants reported an abnormal clinically meaningful laboratory value; one for Strep A2 rapid screen on Day 8, and one for SARS‐CoV‐2 RNA on Day 9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths, serious events, and adverse events of special interest in the congress poster's safety summary
Study limitations
Summary
- The authors advise caution in interpreting the dose proportionality analysis because of the small number of participants, the limited q.d. and Q12 dose range, and the wide 95% CIs; no definitive conclusion could be derived for q.d. doses on Day 1 and Q12 doses on Day 14.
- Participants were 49 healthy adults (36 envudeucitinib, 13 placebo) treated for 14 days at one site.
- The last two cohorts (30 mg Q12 and 60 mg q.d.) were dosed nonfasted, while the other cohorts were dosed fasted.
- The Sponsor was unblinded, and five placebo participants with unexpected ESK-001 plasma concentrations were excluded at the Sponsor's request.
- Some pharmacodynamic samples were collected on Day 13 instead of Day 14, and urine was analyzed for only 3 of the 6 cohorts, with one outlier participant raising the 20 mg q.d. means.
- Erythema, the most common TEAE with headache, was secondary to skin taping for a sample collection procedure.
- The article describes a parallel-group study conducted from April 15, 2022 to September 20, 2022; the ClinicalTrials.gov record lists sequential assignment, a start on 2022-05-12, and completion on 2022-12-31, and reads “No Results Posted”.
Small sample and limited dose range for the dose proportionality analysis
“Furthermore, in the MD study, the results of statistical analysis of the dose proportionality should be cautiously interpreted in light of the small number of participants included in the analysis, the limited q.d. and Q12 dose range examined, and the wide 95% CI around the estimated slopes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote